<html>
<head>
  <title>SARS-CoV-2 Spike protein (S) gene D420N literature reference collection</title>
  <link rel="stylesheet" href="constellations.css">
</head>
<body>
<h1><a href="front.html">SARS-CoV-2</a> <a href="S.html">Spike protein (S)</a> gene <span class="constellation">S:p.D420N</span> literature reference collection</h1>
<div class="effect_section"><h2 id="monoclonal_antibody_serial_passage_escape">Monoclonal antibody serial passage escape</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Escape mutation against monoclonal antibody LY-CoV016 (<a href="https://doi.org/10.1101/2021.02.17.431683" class="lit_link">Starr et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="pharmaceutical_effectiveness">Pharmaceutical effectiveness</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Inhibition of Wuhan-Hu-1 RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected.<br/> (<a href="https://doi.org/10.1101/2022.08.17.504313" class="lit_link">Witte et al. (2022)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected.<br/> (<a href="https://doi.org/10.1101/2022.08.17.504313" class="lit_link">Witte et al. (2022)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected.<br/> (<a href="https://doi.org/10.1101/2022.08.17.504313" class="lit_link">Witte et al. (2022)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected.<br/> (<a href="https://doi.org/10.1101/2022.08.17.504313" class="lit_link">Witte et al. (2022)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Inhibition of Omicron BA.2 RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected.<br/> (<a href="https://doi.org/10.1101/2022.08.17.504313" class="lit_link">Witte et al. (2022)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected.<br/> (<a href="https://doi.org/10.1101/2022.08.17.504313" class="lit_link">Witte et al. (2022)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected.<br/> (<a href="https://doi.org/10.1101/2022.08.17.504313" class="lit_link">Witte et al. (2022)</a>)</span></li>
</ul></div>
<div class="acknowledgement">Automatically generated using text2ui script and data from <a href="https://github.com/nodrogluap/pokay">Pokay</a></div>
</body>
</html>
